… CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017,
… of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory in second …

… acute lymphoblastic leukemia (ALL) and B-cell precursor ALL with minimal residual disease…
Ph− R/R B-cell precursor ALL. The benefits of treating R/R B-cell precursor ALL patients with …

… relapsed/refractory B-cell lymphoma xenografts … B-cell ALL models. In one in vitro study,
inotuzumab ozogamicin demonstrated dose-dependent cellular destruction in a majority of cells …

… in pediatric patients with relapsed/refractory B-cell precursor ALL (BCP-ALL) 4 . In … /refractory
BCP-ALL and > 25% bone marrow blasts if disease was primary refractory or in refractory …

… We report a case of refractory B-cell precursor ALL (BCP-ALL) where the identification of a
genomic alteration activating kinase signaling, the EBF1-PDGFRB fusion, allowed the patient …

… CD3-positive to CD19-positive cells leading to T cell–mediated lysis of CD19 expressing
normal and malignant B cells. It exhibits high activity in the therapy of adult CD19-positive ALL. …

… cell therapy, for the treatment of adult patients with relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (B… -term safety in adult patients with relapsed or refractory B-ALL. …

… We evaluated the relationship between MRD response and outcomes in blinatumomab-treated
adults with relapsed/refractory (R/R) B-cell precursor ALL. Of 90 patients with complete …

… cell engager (BiTE ® ) antibody construct indicated to treat patients with relapsed/refractory
B-precursor … in 70 pediatric patients with relapsed/refractory ALL, with 14 patients achieving …

… T-cell engager, binding T-cell CD3 and B-cell CD19 antigens, has remarkably enlarged the
treatment options for patients with relapsed/refractory B-cell precursor acute lymphoblastic …